Polarean Imaging plc
("Polarean" or the "Company")
Notice of results
Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, confirms that it will be announcing its half year results for the six months ended 30 June 2024 on Wednesday, 4 September 2024.
Christopher von Jako, Ph.D., Chief Executive Officer, and Charles Osborne, Chief Financial Officer, will be hosting a live online presentation relating to the results via the Investor Meet Company platform on Wednesday, 4 September 2024 at 17.30 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your IMC dashboard up until 09:00 BST the day before the meeting or in real time during the presentation.
Investors can sign up to Investor Meet Company for free and add to meet Polarean Imaging plc here. Investors who already follow Polarean on the Investor Meet Company platform will automatically be invited.
Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation will be available on the Investor Meet Company platform afterwards.
Enquiries:
| Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | |||
| Christopher von Jako, Ph.D., Chief Executive Officer Charles Osborne, Chief Financial Officer
| Via Walbrook PR
| |||
| Stifel (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | |||
| Nicholas Moore / Nick Harland / Ben Good | | |||
|
| | |||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com | |||
| Anna Dunphy / Phillip Marriage | Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082 | |||
About Polarean
Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
